

# Cameroon

Population 2016

23 million

Estimates of TB burden*, 2016	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	6.6 (3.9–10)	28 (17–43)
Mortality (HIV+TB only)	6.3 (4–9.2)	27 (17–39)
Incidence (includes HIV+TB)	48 (31–68)	203 (131–290)
Incidence (HIV+TB only)	16 (10–24)	70 (44–100)
Incidence (MDR/RR-TB)**	1.6 (1–2.2)	6.8 (4.3–9.4)

## Estimated TB incidence by age and sex (thousands)\*, 2016

	0-14 years	> 14 years	Total
Females	2.9 (1.8–4.1)	15 (9.2–21)	18 (11–25)
Males	3.3 (2–4.6)	26 (16–36)	29 (18–41)
Total	6.3 (3.8–8.7)	41 (25–57)	48 (31–68)

## TB case notifications, 2016

Total cases notified	25 975
Total new and relapse	25 975
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	93%
- % pulmonary	83%
- % bacteriologically confirmed among pulmonary	74%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2016	55% (38–84)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2016	0.28 (0.16–0.43)

## TB/HIV care in new and relapse TB patients, 2016

	Number	(%)
Patients with known HIV-status who are HIV-positive	8 264	34%
- on antiretroviral therapy	7 575	92%

Drug-resistant TB care, 2016	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			760 (620–890)
Estimated % of TB cases with MDR/RR-TB	2.8% (2.1–3.4)	13% (8.9–17)	
% notified tested for rifampicin resistance		75%	1 541
MDR/RR-TB cases tested for resistance to second-line drugs			176
Laboratory-confirmed cases		MDR/RR-TB: 176, XDR-TB: 1	
Patients started on treatment ****		MDR/RR-TB: 135, XDR-TB: 1	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2015	84%	26 117
Previously treated cases, excluding relapse, registered in 2015	73%	453
HIV-positive TB cases registered in 2015	81%	8 471
MDR/RR-TB cases started on second-line treatment in 2014	81%	91
XDR-TB cases started on second-line treatment in 2014		0

## TB preventive treatment, 2016

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

## TB financing, 2017

National TB budget (US\$ millions)	5
Funding source: 28% domestic, 72% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2016




Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically